Contains Nonbinding Recommendations

Draft Guidance on Brivaracetam

This draft guidance, when finalized, will represent the current thinking of the Food and Drug Administration (FDA, or the Agency) on this topic. It does not establish any rights for any person and is not binding on FDA or the public. You can use an alternative approach if it satisfies the requirements of the applicable statutes and regulations. To discuss an alternative approach, contact the Office of Generic Drugs.

Active Ingredient: Brivaracetam
Dosage Form; Route: Tablet; oral
Recommended Studies: Two Options: Biopharmaceutics Classification System (BCS) Waiver or In Vivo Bioequivalence (BE) Studies

I. BCS Waiver option:
It may be possible to request a waiver of in vivo testing for all the strengths of this product provided that the appropriate documentation regarding high solubility, high permeability and rapid dissolution as detailed in the Guidance for Industry: *Waiver of In-Vivo Bioavailability and Bioequivalence Studies for Immediate – Release Solid Oral Dosage Forms Based on the Biopharmaceutics Classification System (BCS)* is submitted in the application. You may use information contained in the approved labeling of the reference product. Peer reviewed articles may not contain the necessary details of the testing for the Agency to make a judgment regarding the quality of the studies. A decision regarding the acceptability of the waiver request can only be made upon review of the data submitted in the application.

II. In Vivo BE Studies option:
1. Type of study: Fasting
   Design: Single-dose, two-treatment, two-period crossover in-vivo
   Strength: 100 mg
   Subjects: Healthy males and non-pregnant, non-lactating females, general population.
   Additional Comments: None.

2. Type of study: Fed
   Design: Single-dose, two-treatment, two-period crossover in-vivo
   Strength: 100 mg
   Subjects: Healthy males and non-pregnant, non-lactating females, general population.
   Additional Comments: None.

**Analytes to measure (in appropriate biological fluid):** Brivaracetam in plasma (BE study)
**Bioequivalence based on (90% CI):** Brivaracetam

Recommended Jul 2017
**Waiver request of in vivo testing:** 10 mg, 25 mg, 50 mg and 75 mg based on (i) acceptable bioequivalence studies on the 100 mg strength, (ii) proportional similarity of the formulations across all strengths, and (iii) acceptable in vitro disintegration testing of all strengths.

**Dissolution test method and sampling times:** The dissolution information for this drug product can be found on the FDA-Recommended Dissolution Methods web site, available to the public at the following location: [http://www.accessdata.fda.gov/scripts/cder/dissolution/](http://www.accessdata.fda.gov/scripts/cder/dissolution/). Conduct comparative dissolution testing on 12 dosage units of all strengths of the test and reference products. Specifications will be determined upon review of the abbreviated new drug application (ANDA).